美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Brookfield Real Assets Income Fund Inc.

13.30

+0.03000.23%

盘后：13.300.00000.00%19:03 EST

成交量：21.67万

成交额：288.03万

市值：7.35亿

市盈率：9.46

高：13.35

开：13.25

低：13.23

收：13.27

52周最高：13.59

52周最低：11.87

股本：5,525.47万

流通股本：5,524.59万

量比：0.82

换手率：0.39%

股息：1.42

股息率：10.65%

每股收益(TTM):1.41

净资产收益率：--

总资产收益率：--

市净率：0.92

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

新闻稿：Vor Bio任命RA Capital的Andrew Levin博士及Forbion的Wouter Joustra为董事会成员

中国TCE投资地图2025：风暴将至

Anaptysbio, Inc.盘中异动急速上涨5.28%报38.97美元

免疫调节原研药赛能缺货致价格翻倍！已有药店限购，相关企业回应：涨价是市场行为

红星资本局

Anaptysbio, Inc.盘中异动股价大涨5.54%报22.11美元

Anaptysbio, Inc.盘中异动快速拉升5.15%报20.83美元

Anaptysbio, Inc.盘中异动早盘股价大跌5.31%报19.09美元

股价年涨363%破百元，这只股票成山东第四只百元股

处方药网络零售合规指南公开征求意见；侵入式脑机接口获批上市

21世纪经济报道

Sera Prognostics, Inc.盘中异动下午盘股价大跌5.25%报2.89美元

Biomerica, Inc.盘中异动股价大跌6.41%报3.21美元

荣昌生物上半年亏损4.5亿，经营现金流仍吃紧！核心产品BD交易获超5亿首付

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/RA/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RA\",,,,,undefined,":{"symbol":"RA","market":"US","secType":"STK","nameCN":"Brookfield Real Assets Income Fund Inc.","latestPrice":13.3,"timestamp":1770843600000,"preClose":13.27,"halted":0,"volume":216652,"hourTrading":{"tag":"盘后","latestPrice":13.3,"preClose":13.3,"latestTime":"19:03 EST","volume":516,"amount":6863.2225,"timestamp":1770854593732,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0022607385079126707,"floatShares":55245934,"shares":55254696,"eps":1.406,"marketStatus":"未开盘","change":0.03,"latestTime":"02-11 16:00:00 EST","open":13.25,"high":13.345,"low":13.2275,"amount":2880335.910216,"amplitude":0.008855,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.406,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1770886800000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":13.27,"dividendRate":0.106459,"preHourTrading":{"tag":"盘前","latestPrice":13.27,"preClose":13.27,"latestTime":"08:38 EST","volume":1,"amount":13.27,"timestamp":1770817081521,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":13.3,"preClose":13.3,"latestTime":"19:03 EST","volume":516,"amount":6863.2225,"timestamp":1770854593732,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.821474},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RA\",,,,,undefined,":{"symbol":"RA","floatShares":55245934,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.821474,"shares":55254696,"dividePrice":1.4159,"high":13.345,"amplitude":0.008855,"preClose":13.27,"low":13.2275,"week52Low":11.87,"pbRate":"0.92","week52High":13.59,"institutionHeld":0,"latestPrice":13.3,"eps":1.406,"divideRate":0.106459,"volume":216652,"delay":0,"ttmEps":1.406,"open":13.25,"prevYearClose":12.96,"prevWeekClose":13.22,"prevMonthClose":13.02,"prevQuarterClose":12.96,"fiveDayClose":13.16,"twentyDayClose":12.95,"sixtyDayClose":12.97},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RA\",params:#limit:5,,,undefined,":[{"date":"2026-03-12","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-12","defaultRemindTime":1773322200000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-26","payableDate":"2026-03-12","currency":"USD","dateTimestamp":1773288000000,"payDate":"2026-03-26"},{"date":"2026-02-05","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-02-05","defaultRemindTime":1770301800000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-02-19","payableDate":"2026-02-05","currency":"USD","dateTimestamp":1770267600000,"payDate":"2026-02-19"},{"date":"2026-01-08","symbol":"RA","amount":0.118,"announcedDate":"2025-12-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-01-08","defaultRemindTime":1767882600000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-22","payableDate":"2026-01-08","currency":"USD","dateTimestamp":1767848400000,"payDate":"2026-01-22"},{"date":"2025-12-11","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-11","defaultRemindTime":1765463400000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-11","currency":"USD","dateTimestamp":1765429200000,"payDate":"2025-12-26"},{"date":"2025-11-13","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-11-13","defaultRemindTime":1763044200000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-11-28","payableDate":"2025-11-13","currency":"USD","dateTimestamp":1763010000000,"payDate":"2025-11-28"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RA\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-13","recordDate":"2016-12-15","paymentDate":"2016-12-22","value":0.199,"currency":"USD"},{"executeDate":"2017-03-14","recordDate":"2017-03-16","paymentDate":"2017-03-23","value":0.199,"currency":"USD"},{"executeDate":"2017-04-18","recordDate":"2017-04-20","paymentDate":"2017-04-27","value":0.199,"currency":"USD"},{"executeDate":"2017-05-16","recordDate":"2017-05-18","paymentDate":"2017-05-25","value":0.199,"currency":"USD"},{"executeDate":"2017-06-13","recordDate":"2017-06-15","paymentDate":"2017-06-22","value":0.199,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RA\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1171369174","title":"新闻稿：Vor Bio任命RA Capital的Andrew Levin博士及Forbion的Wouter Joustra为董事会成员","url":"https://stock-news.laohu8.com/highlight/detail?id=1171369174","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171369174?lang=zh_cn&edition=fundamental","pubTime":"2025-12-24 05:02","pubTimestamp":1766523754,"startTime":"0","endTime":"0","summary":"波士顿，马萨诸塞州，2025年12月23日-- Vor Biopharma Inc.，一家致力于改变自身免疫疾病治疗的临床阶段生物技术公司，今天宣布任命RA Capital Management的合伙人Andrew Levin博士和Forbion的普通合伙人Wouter Joustra加入其董事会。此次任命是在公司最近宣布的1.5亿美元PIPE融资后进行的，两个投资者均参与了此次融资。Levin博士填补了此前由RA Capital的总法律顾问Sarah Reed担任的职位，后者已辞去董事会职务。本新闻稿中的前瞻性声明包括Vor Bio关于telitacicept发展计划的陈述，以及其他非历史性事实的陈述。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA"],"gpt_icon":0},{"id":"2585459696","title":"中国TCE投资地图2025：风暴将至","url":"https://stock-news.laohu8.com/highlight/detail?id=2585459696","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585459696?lang=zh_cn&edition=fundamental","pubTime":"2025-11-24 15:28","pubTimestamp":1763969338,"startTime":"0","endTime":"0","summary":"如曲妥珠单抗治疗晚期HER2阳性乳腺癌，利妥昔单抗治疗B细胞淋巴瘤。此外，TCE有望走向自免适应症。其中，全球首创的CD19/BCMA/CD3三抗LBL-051通过NewCo模式与Aditum Bio合作，交易总额达6.14亿美元，创下国内临床前TCE管线授权纪录。无独有偶，康诺亚在2025年1月又联合诺诚健华将CD20/CD3双抗CM355非肿瘤适应症权益授予RTW投资的Prolium，分得875万美元首付款，5.025亿美元里程碑潜在收益以及Prolium的部分股权。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1763967554011359814","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["MSS","RA","BK4113"],"gpt_icon":0},{"id":"2585515990","title":"Anaptysbio, Inc.盘中异动 急速上涨5.28%报38.97美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2585515990","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585515990?lang=zh_cn&edition=fundamental","pubTime":"2025-11-20 22:50","pubTimestamp":1763650225,"startTime":"0","endTime":"0","summary":"北京时间2025年11月20日22时50分，Anaptysbio, Inc.股票出现异动，股价急速上涨5.28%。截至发稿，该股报38.97美元/股，成交量2.351万股，换手率0.08%，振幅3.89%。Anaptysbio, Inc.股票所在的生物技术行业中，整体涨幅为1.51%。其相关个股中，Abpro Holdings Inc C/Wts 12/11/2029 、Annexon, Inc.、Design Therapeutics, Inc.涨幅较大，Psyence Biomedical Ltd.、Clearmind Medicine Inc.、Kazia Therapeutics Limited较为活跃，换手率分别为954.91%、37.38%、14.49%，振幅较大的相关个股有Immutep Ltd、Biorestorative Therapies, Inc.、康乃德生物，振幅分别为102.05%、21.68%、20.32%。Anaptysbio, Inc.公司简介：AnaptysBio Inc是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251120225026a706fe38&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251120225026a706fe38&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4132","ANAB","BK4139","RA","AD"],"gpt_icon":0},{"id":"2578634704","title":"免疫调节原研药赛能缺货致价格翻倍！已有药店限购，相关企业回应：涨价是市场行为","url":"https://stock-news.laohu8.com/highlight/detail?id=2578634704","media":"红星资本局","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578634704?lang=zh_cn&edition=fundamental","pubTime":"2025-10-26 17:37","pubTimestamp":1761471463,"startTime":"0","endTime":"0","summary":"“赛能赶上黄金了，一天一个价。”“赛能是不是要停产了，哪里的医院还能开？”近日，红星资本局注意到，硫酸羟氯喹片原研药赛能缺货、涨价的消息在社交平台上传播。资料显示，硫酸羟氯喹是一种广泛应用于治疗自身免疫性疾病的药物，原研药赛能由知名法国药企赛诺菲（Sanofi）生产，2000年在国内获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510263544477885.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["SLE","BK4077","RA"],"gpt_icon":0},{"id":"2570035316","title":"Anaptysbio, Inc.盘中异动 股价大涨5.54%报22.11美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2570035316","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570035316?lang=zh_cn&edition=fundamental","pubTime":"2025-09-24 21:43","pubTimestamp":1758721408,"startTime":"0","endTime":"0","summary":"北京时间2025年09月24日21时43分，Anaptysbio, Inc.股票出现波动，股价急速拉升5.54%。截至发稿，该股报22.11美元/股，成交量5.2759万股，换手率0.19%，振幅4.58%。Anaptysbio, Inc.股票所在的生物技术行业中，整体跌幅为0.01%。其相关个股中，Uniqure N.V.、Osr Holdings Inc C/Wts 09/02/2028 、Cyclerion Therapeutics, Inc.涨幅较大，Cyclerion Therapeutics, Inc.、Jaguar Health, Inc.、Uniqure N.V.较为活跃，换手率分别为347.15%、35.38%、28.21%，振幅较大的相关个股有Uniqure N.V.、Pharmacyte  Biotech, Inc.、Briacell Therapeutics Corp C/Wts 26/02/2026，振幅分别为35.58%、28.69%、20.87%。Anaptysbio, Inc.公司简介：AnaptysBio Inc是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250924214329a69b797d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250924214329a69b797d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ANAB","RA","BK4132","BK4139","AD"],"gpt_icon":0},{"id":"2568285278","title":"Anaptysbio, Inc.盘中异动 快速拉升5.15%报20.83美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2568285278","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568285278?lang=zh_cn&edition=fundamental","pubTime":"2025-09-19 02:27","pubTimestamp":1758220046,"startTime":"0","endTime":"0","summary":"北京时间2025年09月19日02时27分，Anaptysbio, Inc.股票出现异动，股价快速拉升5.15%。Anaptysbio, Inc.股票所在的生物技术行业中，整体涨幅为0.37%。Anaptysbio, Inc.公司简介：AnaptysBio Inc是一家临床阶段的生物技术公司。消息层面，截至02时27分，《韦德布什维持AnaptysBio买入评级，维持目标价45美元》资讯为影响Anaptysbio, Inc.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202509190227279536fbfc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202509190227279536fbfc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4132","ANAB","BK4139","AD","RA"],"gpt_icon":0},{"id":"2568480974","title":"Anaptysbio, Inc.盘中异动 早盘股价大跌5.31%报19.09美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2568480974","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568480974?lang=zh_cn&edition=fundamental","pubTime":"2025-09-16 21:39","pubTimestamp":1758029970,"startTime":"0","endTime":"0","summary":"北京时间2025年09月16日21时39分，Anaptysbio, Inc.股票出现波动，股价急速下跌5.31%。截至发稿，该股报19.09美元/股，成交量8.8507万股，换手率0.32%，振幅5.83%。Anaptysbio, Inc.股票所在的生物技术行业中，整体涨幅为0.16%。其相关个股中，Aptevo Therapeutics Inc.、Surrozen Inc C/Wts 01/08/2031 、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Aptevo Therapeutics Inc.、Silo Pharma, Inc.、Enveric Biosciences, Inc.较为活跃，换手率分别为1847.59%、102.23%、74.24%，振幅较大的相关个股有Aptevo Therapeutics Inc.、Adaptimmune Therapeutics Plc、冠科美博，振幅分别为40.97%、31.68%、19.16%。Anaptysbio, Inc.公司简介：AnaptysBio Inc是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250916213930a4c9ac98&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250916213930a4c9ac98&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ANAB","BK4132","AD","RA","BK4139"],"gpt_icon":0},{"id":"2566862227","title":"股价年涨363%破百元，这只股票成山东第四只百元股","url":"https://stock-news.laohu8.com/highlight/detail?id=2566862227","media":"经济导报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566862227?lang=zh_cn&edition=fundamental","pubTime":"2025-09-10 13:47","pubTimestamp":1757483220,"startTime":"0","endTime":"0","summary":"9月9日，荣昌生物股价突破100元，盘中最高价达111.6元，较年内股价最低点24.11元大涨363%。目前，其已成为山东第四只股价超过百元的股票。在股价突破百元的当日，该公司宣布泰它西普治疗干燥综合征的上市申请获国家药品监督管理局药品审评中心受理，成为干燥综合征领域全球首个申请上市的生物药。截至2025年6月30日，自身免疫商业化团队、肿瘤商业化团队均已完成超过1000家医院的药品准入。","market":"us","thumbnail":"http://imgcloud.jrjimg.cn/2025/09/weixin/one_20250910134720351.png","type":0,"news_type":0,"thumbnails":["http://imgcloud.jrjimg.cn/2025/09/weixin/one_20250910134720351.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.jrj.com.cn/2025/09/10134753043697.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4017","LU1997244956.HKD","LU1251922891.USD","300779","LU2580892789.USD","HK0000306685.HKD","BK0214","IE00BYQNZ168.SGD","LU1719994722.HKD","BK0028","BK1583","LU2328871848.SGD","RA","LU0164939612.USD","LU1655091616.SGD","BK0070","LU1223082519.USD","LU2488822045.USD","SGXZ49509284.SGD","09995","LU0620787316.HKD","SGXZ81163826.USD","BK0239","LU0871576103.HKD","CDE","IE00B12V2V27.USD","BK1161","LU0082770016.USD","HK0000320264.USD","LU2495084118.USD","LU1770034418.SGD","688190","300308","BK0255","LU1969619763.USD","LU0531971595.HKD","LU1064130708.USD","BK0212","688331","SG9999011746.SGD","HK0000306701.USD","BK4077","BK1574","LU1223083913.SGD","IE0034224299.USD","SLE","LU0039217434.USD","LU1223082196.USD","IE00BYTNYN87.SGD","LU1064131003.USD"],"gpt_icon":0},{"id":"2566647565","title":"处方药网络零售合规指南公开征求意见；侵入式脑机接口获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2566647565","media":"21世纪经济报道","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566647565?lang=zh_cn&edition=fundamental","pubTime":"2025-09-10 08:36","pubTimestamp":1757464619,"startTime":"0","endTime":"0","summary":"政策动向处方药网络零售合规指南公开征求意见为切实保障网络零售药品质量安全，规范处方药网络零售行为，提高药品网络零售相关从业者的合规意识，落实药品安全主体责任，国家药监局组织起草了《处方药网络零售合规指南（征求意见稿）》，并社会公开征求意见。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202509103509342159.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202509103509342159.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["RA","BK4077","CDE","LU1223083913.SGD","BK4017","LU1223082196.USD","LU1223082519.USD","BCI","SLE"],"gpt_icon":0},{"id":"2562158775","title":"Sera Prognostics, Inc.盘中异动 下午盘股价大跌5.25%报2.89美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2562158775","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562158775?lang=zh_cn&edition=fundamental","pubTime":"2025-08-28 02:45","pubTimestamp":1756320328,"startTime":"0","endTime":"0","summary":"北京时间2025年08月28日02时45分，Sera Prognostics, Inc.股票出现异动，股价急速下挫5.25%。截至发稿，该股报2.89美元/股，成交量6.6621万股，换手率0.18%，振幅6.83%。Sera Prognostics, Inc.股票所在的医疗器械行业中，整体跌幅为0.02%。其相关个股中，Ainos Inc C/Wts 29/07/2027 、Electromed, Inc.、Adagio Medical Holdings, Inc涨幅较大，Aethlon Medical, Inc.、飞天兆业、Profusa, Inc.较为活跃，换手率分别为18.44%、12.67%、10.68%，振幅较大的相关个股有Nexalin Technology Inc C/Wts 、Ainos Inc C/Wts 29/07/2027 、Adagio Medical Holdings, Inc，振幅分别为63.20%、46.21%、35.45%。Sera Prognostics, Inc.公司简介：Sera Prognostics Inc 是一家健康诊断公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250828024528976568fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250828024528976568fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","SERA","RA","BK4139"],"gpt_icon":0},{"id":"2562715958","title":"Biomerica, Inc.盘中异动 股价大跌6.41%报3.21美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2562715958","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562715958?lang=zh_cn&edition=fundamental","pubTime":"2025-08-26 21:33","pubTimestamp":1756215183,"startTime":"0","endTime":"0","summary":"北京时间2025年08月26日21时33分，Biomerica, Inc.股票出现波动，股价快速下跌6.41%。截至发稿，该股报3.21美元/股，成交量1.1154万股，换手率0.44%，振幅2.62%。Biomerica, Inc.股票所在的医疗器械行业中，整体跌幅为0.03%。Biomerica, Inc.公司简介：Biomerica公司致力于开发、制造和销售医疗诊断产品，用于慢性疾病和医疗状况的早期检测和监测。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250826213303a6fcd8f7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250826213303a6fcd8f7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RA"],"gpt_icon":0},{"id":"2561250644","title":"荣昌生物上半年亏损4.5亿，经营现金流仍吃紧！核心产品BD交易获超5亿首付","url":"https://stock-news.laohu8.com/highlight/detail?id=2561250644","media":"时代周报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561250644?lang=zh_cn&edition=fundamental","pubTime":"2025-08-23 20:47","pubTimestamp":1755953238,"startTime":"0","endTime":"0","summary":"荣昌生物虽在上半年实现亏损大幅缩窄，但仍面临较大的现金流压力。2025年上半年，荣昌生物经营现金流净额虽同比增长，但仍然为负。同时，荣昌生物上半年货币资金为12.74亿元，短期借款则高达13.21亿元，资产负债率达到59.70%。2025年上半年，荣昌生物的出海BD交易引发行业广泛关注。在完成泰它西普的对外授权交易后，荣昌生物继续推动其他创新药产品的BD交易，并于近日再度达成一则对外授权交易。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025082320473194f6e9a9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025082320473194f6e9a9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","BC","LU0868494617.USD","IE0002270589.USD","BK4080","BK4588","LU0306806265.USD","LU0306807586.USD","LU0456855351.SGD","SGXZ57979304.SGD","LU0058720904.USD","LU1883839398.USD","LU0225284248.USD","SG9999001176.USD","BK4123","IE00BLSP4239.USD","LU0225771236.USD","SLE","BK4533","LU1066053197.SGD","BK4592","LU1894683264.USD","BK4585","IE00B66KJ199.SGD","IE00B19Z4B17.USD","BK4581","RA","MG","BK4007","SG9999013999.USD","IE00B19Z3581.USD","BK4231","IE00BLSP4452.SGD","LU1066051498.USD","LU0234572021.USD","SG9999011175.SGD","LU1023059063.AUD","IE0031619046.USD","SG9999003800.SGD","LU0321505439.SGD","LU0289739699.SGD","IE000M9KFDE8.USD","IE00BBT3K403.USD","LU0985481810.HKD","SG9999002232.USD","BK4568","LU0170899867.USD","SG9999001176.SGD","ADC"],"gpt_icon":1}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":12,"code":"91000000","status":"200"}]}}